Equity Profile

RYTM

RHYTHM PHARMACEUTICA

Health CareBiotechnology$5.9B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Rhythm Pharmaceuticals (RYTM) is a biotechnology company focused on developing treatments for rare genetic disorders that cause obesity. With a market cap of $6 billion, the company is positioned within the healthcare sector, which is increasingly focused on personalized medicine and innovative therapies.

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RYTM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-1.49%

Avg Stock Reaction

+1.37%

Last Quarter Recap

In Q1-2026, Rhythm Pharmaceuticals reported an EPS of -$0.83, which was better than the expected -$0.86, resulting in a positive stock reaction of 7.86% the next day. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Rhythm Pharmaceuticals' upcoming earnings report, especially after a slight EPS beat last quarter. However, the lack of revenue guidance creates uncertainty.

Bull Case

If the company can show strong progress in its drug development pipeline and report better-than-expected revenue growth, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its product pipeline, it could lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug pipeline and any upcoming clinical trial results?

Updates on the drug pipeline can significantly impact investor sentiment and stock performance, especially if there are promising developments.

Will the company provide any revenue guidance for the upcoming quarters?

Clear revenue guidance is crucial for setting market expectations and can influence stock price movements post-earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of upcoming clinical trial results, which could significantly boost investor confidence and stock performance.

Supporting Evidence

Options are pricing a larger move than historical averages, indicating heightened expectations.

The company's recent EPS surprise suggests potential for better-than-expected results.

Key Risk

If the company announces a major breakthrough in its drug pipeline, it could dramatically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the uncertainty surrounding the company's product pipeline and revenue generation.

Bull Confirmed If

A positive update on the drug pipeline with potential for significant revenue growth would confirm the bull case.

Bear Confirmed If

Failure to provide any revenue guidance or negative updates on the drug pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±11.61%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant move of about 11.61%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±11.6% while RYTM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.6%

Calls (900)P/C Ratio: 0.44Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations and raises guidance, history suggests the stock could rise by around 3.24% on the day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction.

Miss

A miss on earnings could lead to a decline of about 0.50% based on historical patterns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any upcoming clinical trial results.
2Revenue guidance for the upcoming quarters.
3Management's commentary on market conditions and competitive landscape.
4Any changes to the company's strategic direction or focus areas.
5Insights into partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RYTM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-1.49%

Avg Stock Reaction

+1.37%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If the company can show strong progress in its drug development pipeline and report better-than-expected revenue growth, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its product pipeline, it could lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug pipeline and any upcoming clinical trial results?

Updates on the drug pipeline can significantly impact investor sentiment and stock performance, especially if there are promising developments.

Will the company provide any revenue guidance for the upcoming quarters?

Clear revenue guidance is crucial for setting market expectations and can influence stock price movements post-earnings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of upcoming clinical trial results, which could significantly boost investor confidence and stock performance.

Supporting Evidence

Options are pricing a larger move than historical averages, indicating heightened expectations.

The company's recent EPS surprise suggests potential for better-than-expected results.

Key Risk

If the company announces a major breakthrough in its drug pipeline, it could dramatically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the uncertainty surrounding the company's product pipeline and revenue generation.

Bull Confirmed If

A positive update on the drug pipeline with potential for significant revenue growth would confirm the bull case.

Bear Confirmed If

Failure to provide any revenue guidance or negative updates on the drug pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±11.61%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant move of about 11.61%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±11.6% while RYTM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.6%

Calls (900)P/C Ratio: 0.44Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations and raises guidance, history suggests the stock could rise by around 3.24% on the day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction.

Miss

A miss on earnings could lead to a decline of about 0.50% based on historical patterns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any upcoming clinical trial results.
2Revenue guidance for the upcoming quarters.
3Management's commentary on market conditions and competitive landscape.
4Any changes to the company's strategic direction or focus areas.
5Insights into partnerships or collaborations that could enhance growth.